Navigation Links
St. Jude Finds More Than 100 Gene Variations Linked With Response to Leukemia Treatment
Date:1/27/2009

Scan of thousands of inherited genetic changes reveal specific variations linked to treatment failure and the fate of chemotherapy drugs in the body for children with acute lymphoblastic leukemia

MEMPHIS, Tenn., Jan. 27 /PRNewswire-USNewswire/ -- Scientists from St. Jude Children's Research Hospital and the Children's Oncology Group (COG) have discovered in children with acute lymphoblastic leukemia (ALL) scores of inherited genetic variations that clinicians might be able to use as guideposts for designing more effective chemotherapy for this cancer.

The findings are important because although cure rates for ALL exceed 80 percent, patient responses vary significantly to the same drugs. Much of this variance has been unexplained. The newly discovered genetic variations, however, will likely give scientists a clearer understanding of why treatments fail in some patients with ALL, and how to predict early in treatment which children could be successfully treated with less aggressive treatment.

"This study differs from most previous investigations of gene variations linked to chemotherapy outcome because those studies focused only on the genes of the leukemic cells themselves," said Mary Relling, Pharm.D., St. Jude Pharmaceutical Sciences chair. "We focused on genomic variation that is inherited and affects all cells in the body, not just the leukemic cells." Relling is the senior author of a report on the team's study that appears in the January 28, 2009, issue of the Journal of the American Medical Association.

In their research, St. Jude scientists collaborated with a team from COG, a worldwide group of medical institutions that cooperate in laboratory research studies and clinical trials of cancer treatments for children. Instead of studying genetic variations acquired by leukemia cells, scientists identified small genetic variations the children inherited from their parents.

The researchers then determined which of those small, inherited variations, called single-nucleotide polymorphisms (SNPs), were associated with minimal residual disease (MRD). MRD is the small number of leukemic cells that survive after remission induction therapy -- the initial treatment. This measurement helps clinicians identify patients whose disease is highly responsive to chemotherapy and therefore might be cured with milder and less-toxic treatment, and also shows if remission induction therapy will likely fail.

The researchers performed a search of 476,796 inherited SNPs from two independent groups of children with newly diagnosed ALL: 318 patients on clinical trials at St. Jude and 169 patients on COG clinical trials.

The study discovered 102 of the inherited genetic variations that affected the level of residual leukemia or MRD. A high proportion (21 of 102) of these MRD-linked SNPs also predicted leukemic relapse; moreover, 21 SNPs linked eradication of MRD with greater exposure of the leukemic cells to the chemotherapy drugs.

For example, the researchers discovered five SNPs that are located in and around a gene called IL15, which codes for a protein called interleukin 15 that stimulates multiplication of leukemic cells. The finding was significant because previous studies showed that IL15 protects tumors from certain chemotherapy drugs; and that it is linked to both invasion of the central nervous system by leukemic cells and an increased risk of recurrence in that area following treatment. In the current study, the team found a link between the IL15 SNPs, increased levels of IL15 in leukemia cells, and an increased risk of high MRD at the end of induction therapy.

"Our finding that IL15 plays such an important role in the failure of chemotherapy suggests that this gene may be a marker we could use to predict outcome of therapy," Relling said. "IL15 might also represent a new target for novel drugs that knock out its activity and improve the outcome of patients with high levels of this interleukin."

In addition, 21 of the 102 SNPs that predicted MRD also significantly associated with the pharmacokinetics of two antileukemic drugs, etoposide and methotrexate, which are representative of the array of antileukemic medications used to treat lymphoblastic leukemia. Pharmacokinetics comprises the various biochemical fates of a drug in the body--absorption, distribution throughout the body, breakdown and excretion. In almost all cases, gene variation predicting faster elimination of the drugs from the body was associated with higher levels of MRD, suggesting that higher drug doses may be able to overcome the problem of low drug exposure related to an inherited tendency for fast drug elimination, Relling said.

Overall, 63 of the 102 SNPs were associated with early response to therapy, with relapse or with pharmacokinetics of drugs.

Few of the 102 SNPs the team identified in this study had previously been suggested by other investigators to be likely to affect the outcome of ALL chemotherapy. This suggests the need for further research using whole-genome approaches to identify SNPs that affect how individual patients will respond to chemotherapy, Relling said.

"Our results show the importance of surveying variations in the entire human genome in normal cells from patients, since many such variations can determine the effectiveness of chemotherapy," said Jun Yang, Ph.D., a fellow in the St. Jude Department of Pharmaceutical Sciences and the paper's first author. "It also showed that our genome-wide approach to identifying such SNPs is useful for identifying genetic variations that can be used to predict treatment outcomes. In the future, such information might help clinicians use drugs more effectively to overcome the patient's own genetic variation and reduce the chance of treatment failure."

Other authors of this paper include Cheng Cheng, Wenjian Yang, Deqing Pei, Xueyuan Cao, Yiping Fan, Stan Pounds, Geoffrey Neale, Lisa R. Trevino, Deborah French, Dario Campana, James R. Downing, William E. Evans, Ching-Hon Pui (St. Jude); Meenakshi Devidas (University of Florida, Gainesville, Fla.); W.P. Bowman (Cook Children's Medical Center, Ft. Worth, Texas); Bruce M. Camitta (Medical College of Wisconsin, Milwaukee, Wis.); Cheryl Willman (University of New Mexico Cancer Center, Albuquerque, N.M.); Stella Davies (Cincinnati Children's Hospital and Medical Center, Cincinnati); Michael J. Borowitz (Johns Hopkins Medical Institute, Baltimore); William L. Carroll (New York University Medical Center, New York); and Stephen P. Hunger (The Children's Hospital and the University of Colorado Cancer Center, Aurora, Colo.).

This study was supported by the National Institutes of Health, the National Cancer Institute, the National Institute of General Medical Sciences Pharmacogenetics Research Network, CureSearch and ALSAC.

St. Jude Children's Research Hospital

St. Jude Children's Research Hospital is internationally recognized for its pioneering work in finding cures and saving children with cancer and other catastrophic diseases. Founded by late entertainer Danny Thomas and based in Memphis, Tenn., St. Jude freely shares its discoveries with scientific and medical communities around the world. No family ever pays for treatments not covered by insurance, and families without insurance are never asked to pay. St. Jude is financially supported by ALSAC, its fundraising organization. For more information, please visit www.stjude.org.

Children's Oncology Group

The Children's Oncology Group/CureSearch Children's Oncology Group (COG), the world's largest cooperative pediatric cancer research organization, which includes every recognized pediatric cancer program in North America, comprises a network of more than 5,000 physician, nurse, and other clinical and laboratory investigators whose collaboration in clinical and translational research has turned childhood cancer from a virtually incurable disease to one with an overall cure rate approaching 80%. COG is committed to conquering childhood cancer through scientific discovery and compassionate care. For more information, please visit www.childrensoncologygroup.org


'/>"/>
SOURCE St. Jude Children's Research Hospital
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Thomson Reuters Study Finds Sharp Increase in Use of Sleep Medications by Young Adults
2. Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer
3. K-State Researcher Finds Correlation Between Childhood Obesity and Asthma
4. Genomas Clinical Study Finds Increased Prevalence of Drug Metabolism Deficiencies in Patients With Serious Psychotropic Side Effects
5. Observational Study Finds Changes in Medicare Reimbursement for Erythropoiesis-Stimulating Agents Associated With Increased Need for Blood Transfusion
6. Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Dont Get Their Families Vaccinated
7. Physicians Health Study II Finds No Magic Bullet for Preventing Cardiovascular Disease
8. Healthy Bones Program Reduces Hip Fractures by 37 Percent, Kaiser Permanente Study Finds
9. Grapes May Aid a Bunch of Heart Risk Factors, U-M Animal Study Finds
10. Eating Walnuts Slows Cancer Growth, Laboratory Study Finds
11. St. Jude Study Finds Treatment With New Drug Might Make Tumor Cells More Sensitive to Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of ... Farma Brasil as the company,s second affiliate in Latin America . ... ... Manager of Astellas Farma Colombia ... ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, ... minimum wage raise to $12 an hour by 2020 and then adjusting it yearly to ... value of the minimum wage, assure the wage floor does not erode again, and make ...
Breaking Medicine News(10 mins):